english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Prescrire's finances: 2022 annual report

Every year, Association Mieux Prescrire, the legal entity responsible for Prescrire's publications, publishes a summary of its annual financial report in the March issue of Prescrire and in the June issue of Prescrire International. The summary of its 2022 annual report is publicly available here.
1 June 2023

Recombinant Beta variant covid-19 vaccine with adjuvant (Vidprevtyn Beta°), as a booster

 COVID-19  The recombinant Beta variant covid-19 vaccine with AS03 adjuvant was authorised in the European Union in mid-November 2022, for use only as a booster in adults who have already received an mRNA or viral-vector vaccine.
Full article (2 pages) available for download by subscribers
1 June 2023

A difficult choice

 Editorial  Corticosteroids have been used for a very long time, and a great deal is known about their adverse effect profile. In some chronic inflammatory diseases, other drugs with immunosuppressive effects are proposed, with the aim of reducing corticosteroid use. These drugs' adverse effects differ in part from those of corticosteroids, but some of them may not yet be known.
1 May 2023

Anifrolumab (Saphnelo°) in systemic lupus erythematosus after failure of standard therapy

 Marketing Authorisations  Anifrolumab is a monoclonal antibody that inhibits receptors for type I interferons. This immunosuppressant has been authorised in the European Union as add-­on therapy for patients with systemic lupus erythematosus in whom standard treatment has been insufficiently effective.
Full article (3 pages) available for download by subscribers
1 May 2023

Dabigatran (Pradaxa°) for venous thrombosis in children and adolescents

 Marketing Authorisations  Dabigatran, an anticoagulant of the thrombin inhibitor class authorised for use in adults after venous thrombosis, a situation in which it does not represent a therapeutic advance, has now also been authorised for patients less than 18 years of age.
Full article (2 pages) available for download by subscribers
1 May 2023

Janus kinase inhibitors: higher incidence of serious adverse effects and death than with TNF-alpha inhibitors

 Adverse Effects  The increased incidence of serious adverse effects associated with tofacitinib and baricitinib, and probably also the three other JAK inhibitors used in chronic inflammatory diseases, raises questions about the harm-benefit balance of drugs of this class.
Full article (1 page) available for download by subscribers
1 May 2023

Dutasteride, finasteride: high-grade prostate cancer (continued)

 Adverse Effects  In the early 2010s, a trial of finasteride versus placebo in about 19 000 men with no clinical signs of prostate cancer found a decrease in the total number of diagnoses of prostate cancer in the finasteride group, but an increased incidence of particularly aggressive prostate cancer.
Full article (2 pages) available for download by subscribers
1 May 2023

Order of magnitude

 Editorial  In many fields, such as aeronautical or mechanical engineering, accurate measurements and precise execution are essential. This is also true in some fields of medicine, such as pathology, where treatment decisions can hinge on the accuracy of a histological description or test result. However, in medicine in general and health care in particular, accurate measurements are not always available.
1 April 2023

Prescrire's ratings of new drugs in 2022

  Marketing Authorisations  Only 11 of the 124 new marketing authorisations analysed and rated in our French edition in 2022 represented a notable therapeutic advance for patients.
1 April 2023

Belimumab (Benlysta°) in lupus nephritis

  Marketing Authorisations  Belimumab, a monoclonal antibody directed against a protein called BLyS (B lymphocyte stimulator), was initially authorised in the European Union for subcutaneous or intravenous use in systemic lupus erythematosus. It has now also been authorised for use in active lupus nephritis.
1 April 2023

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90